In addition, neuroblastomas in general, and especially those harbouring MYCN amplification37, have a highly immunosuppressive tumour microenvironment such that future iterations of PC-CARs may require additional engineering to enable T cells to navigate to the pMHC complex target. This evidence concerns the gene MYCN and neuroblastoma.